Search

1 to 10 of 13
Sort by

Library Entry
Defining current gaps in quality measures for cancer immunotherapy: consensus report from the Society for Immunotherapy of Cancer (SITC) 2019 Quality Summit

Quality measures are important because they can help improve and standardize the delivery of cancer care among healthcare providers and across tumor types. In an environment characterized by a rapidly shifting immunotherapeutic landscape and lack of associated long-term outcome data, defining...


Library Entry
Adoption of immunotherapy in the community for patients diagnosed with metastatic melanoma

The introduction of immune checkpoint inhibitors has led to a survival benefit in patients with advanced melanoma; however data on the adoption of immunotherapy in the community are scarce. Using the National Cancer Database, the authors identified 4725 patients aged ≥20 diagnosed with...


Library Entry
Challenges in assessing the clinical utility and economic value of immune checkpoint inhibitor therapies of cancer

Advances in the immunotherapy of cancer have prolonged survival for cancer patients, but the clinical and financial impact of treatments must be considered in determining the overall clinical utility and economic value of therapeutic agents. Quality-adjusted life years and incremental cost...


Library Entry
The promise of Immuno-oncology: implications for defining the value of cancer treatment

The rapid development of immuno-oncology (I-O) therapies for multiple types of cancer has transformed the cancer treatment landscape and brightened the long-term outlook for many patients with advanced cancer. Responding to ongoing efforts to generate value assessments for novel therapies,...


Web Page
2015

Immuno-Oncology Policy Working Group The Immuno-Oncology Policy Working Group launched in December 2015 to develop a strategic policy plan to accelerate progress for immune-oncology in multiple disease types and settings. SITC is co-leading this initiative, joining Friends of Cancer Research ,...


Web Page
2016

21st Century Cures Act On December 7, 2016, the U.S. Senate approved the 21st Century Cures Act, a wide-ranging health bill whose passage ensured the American government's commitment to curing cancer. President Barack Obama signed the bill into law soon there after. The 21st Century Cures Act...


Web Page
Standards & Quality of Care

SITC is the first and only organization dedicated to cancer immunotherapy to be accepted as a formal member of the Commission on Cancer (CoC), a program of the American College of Surgeons. SITC 2019 Quality Summit Consensus Report Published on Jan. 16, 2020, in the Journal for ImmunoTherapy of...


Web Page
Policy & Advocacy

Learn about how the Society for Immunotherapy of Cancer advocating toward the advancement of cancer immunotherapy research. Activities include Joe Biden's Cancer Moonshot Initiative, 21st Century Cures Act and more.


Web Page
Regulatory Issues

SITC leaders have prioritized Adverse Events Reporting, Clinical Trial Design/Endpoints and Combination Approaches in approaching regulatory issues relating to the field of cancer immunotherapy. Society for Immunotherapy of Cancer (SITC) leaders have prioritized the following areas of focus in...


Web Page
Journal for ImmunoTherapy of Cancer

The Journal for ImmunoTherapy of Cancer (JITC) is the official journal of the Society for Immunotherapy of Cancer. This open access, peer-reviewed journal publishes original research articles, literature reviews, position papers and more on all aspects of tumor immunology and cancer...